Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease Clinical Trial

Official title:
A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01978587
Study type	Interventional
Source	Akros Pharma Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	October 2013
Completion date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02228655` - An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD	Phase 0
Completed	`NCT04197778` - Food Effect Study of DDO-3055 Tablets in Healthy Subjects	Phase 1
Completed	`NCT01599507` - Study of FG-4592 in Subjects With Chronic Kidney Disease in China	Phase 2